"Billionaire" and "successful hedge fund manager" are titles that carry significant weight on Wall Street. These and others ...

European stocks look like newly good investments amid Trump's tariff war and US economic unpredictabilities. European defense stocks are particularly appealing.

An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as ...

Amgen (AMGN) is a biotech company based in California. It specializes in developing treatments for cardiovascular conditions, ...

Mehmet Oz will likely face questions during his confirmation hearing about his past support of expanding the Medicare ...

Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 ...

Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...

Wegovy and Zepbound — are cutting prices to make the medications more affordable for people without insurance.

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

Eli Lilly CEO Dave Ricks made $114 million last year, according to a new proxy statement, a rare instance of a health ...

The exact price depends on dosage, pharmacy, location, insurance coverage, and available savings programs. Fully understanding the various factors affecting ...

Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available ...